Skip to main content

Advertisement

Table 2 Univariate analyses of prognostic factors for 74 NSCLC patients with postoperative locoregional recurrence treated with radical radiotherapy

From: Survival and prognostic factors of non-small cell lung cancer patients with postoperative locoregional recurrence treated with radical radiotherapy

Variable OS PFS LRFS DMFS
HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age (≥ 59 vs. < 59 years) 1.387 (0.517–3.723) 0.516 0.532 (0.264–1.071) 0.077 0.789 (0.322–1.932) 0.604 0.619 (0.296–1.292) 0.201
Sex (male vs. female) 0.694 (0.197–2.443) 0.570 1.234 (0.603–2.527) 0.565 0.898 (0.324–2.492) 0.837 1.286 (0.605–2.735) 0.513
Stage of primary tumor (I vs. II vs. III) 1.308 (0.700–2.447) 0.400 1.173 (0.775–1.775) 0.451 1.084 (0.643–1.827) 0.762 1.189 (0.758–1.863) 0.451
Histology (squamous cell carcinoma vs. non-squamous cell carcinoma) 0.755 (0.261–2.183) 0.604 1.125 (0.510–2.482) 0.770 0.750 (0.270–2.085) 0.582 1.420 (0.582–3.466) 0.441
Recurrence site (stump vs. regional lymph nodes vs. ipsilateral lung vs. multiple sites) 1.292 (0.689–2.423) 0.425 1.284 (0.767–2.149) 0.342 1.439 (0.780–2.655) 0.245 1.433 (0.840–2.445) 0.187
Interval between surgery and recurrence (≥ 10 vs. < 10 months) 0.882 (0.328–2.373) 0.803 0.690 (0.352–1.351) 0.279 1.054 (0.434–2.559) 0.908 0.655 (0.320–1.339) 0.246
BED of radiation (≥ 78 vs. < 78 Gy) 0.347 (0.119–1.013) 0.053 0.905 (0.466–1.758) 0.769 0.288 (0.104–0.795) 0.016 1.075 (0.531–2.175) 0.841
Concurrent chemotherapy (yes vs. no) 1.222 (0.348–4.294) 0.754 1.114 (0.485–2.555) 0.799 1.247 (0.412–3.774) 0.696 1.150 (0.471–2.808) 0.758
EGFR status (wild-type vs. mutation type vs. unknown) 0.265 (0.063–1.112) 0.069 0.509 (0.238–1.088) 0.509 1.694 (0.465–6.175) 0.425 0.418 (0.192–0.912) 0.028
Radiation technique (3D-CRT vs. IMRT vs. SBRT) 2.562 (0.887–7.395) 0.082 1.213 (0.554–2.654) 0.630 2.047 (0.757–5.537) 0.158 1.130 (0.472–2.701) 0.784
GTV (≥ 28.7 vs. < 28.7 cm3) 1.864 (0.637–5.455) 0.256 1.246 (0.593–2.617) 0.561 0.543 (0.201–1.470) 0.230 1.525 (0.682–3.411) 0.304
  1. OS overall survival, PFS progression-free survival, LRFS local recurrence-free survival, DMFS distant metastasis-free survival, HR hazard ratio, CI confidence interval, BED biological effective dose, EGFR epidermal growth factor receptor, 3D-CRT 3-dimensional conformal radiotherapy, IMRT intensity-modulated radiotherapy, SBRT stereotactic body radiotherapy, GTV gross tumor volume